Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)

Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell lymphoma (DLBCL) and mantle-cell lymphoma (MCL)—proceed directly to first-line treatment, whereas asymptomatic patients with indolent NHL—follicular lymphoma (FL)—are often managed with watchful waiting. Despite NHL subtype-specific considerations, rituximab-based regimens remain foundational across the disease spectrum. Recent regulatory approvals and label expansions are giving physicians an increasing array of treatment options, including Polivy (Roche/Genentech/Chugai) for previously untreated DLBCL, Epkinly (Genmab / AbbVie) for relapsed/refractory (R/R) DLBCL and FL, Brukinsa (BeOne Medicines) and Monjuvi (Incyte) for R/R FL, Breyanzi (Bristol Myers Squibb) for R/R FL and MCL, Adcetris (Pfizer/Takeda) for R/R DLBCL, and Calquence (AstraZeneca) for previously untreated MCL. These advances, alongside shifting prescribing patterns and increasing competition, are reshaping the treatment of NHL.

Questions answered

• What are the uptake and patient share of key therapies and regimens across all NHL subtypes?
• How do drug treatment rates vary across key NHL subtypes by therapy line?
• What are the key drivers and obstacles determining current prescribing patterns in NHL?
• What are the clinical characteristics that physicians consider when prescribing CAR T-cell therapies and bispecific antibodies for the various NHL subtypes?

Product description

• Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.

Primary research: Survey of 100 U.S. hematologist-oncologists.

Key drugs covered: Adcetris, Breyanzi, Brukinsa, Calquence, Columvi, Epkinly, Gazyva, Imbruvica, Jaypirca, Kymriah, Lunsumio, Monjuvi, Polivy, rituximab, Tazverik, Tecartus, Xpovio, Yescarta, Zynlonta